Xiamen blows the trumpet of accelerating the high-quality development of the biopharmaceutical industry

"
Pharmaceutical Network Policy and Regulation" It is learned that Xiamen City has recently issued a series of favorable policies to accelerate the promotion of high-quality development of the biopharmaceutical industryAmong them, "Xiamen City to accelerate the development of high-quality biopharmaceutical industry" will be from the promotion of research and development innovation ability, the expansion of industrial development and energy level, blowing the sound of accelerating the promotion of high-quality development of the biopharmaceutical industry, to create a distinctive national biopharmaceutical industry cluster horn; 2020-2022) clearly, by 2022, the biopharmaceutical industry state-level high-tech enterprises reached 400, the bio-pharmaceutical industry scale of 120 billion, become the national strategic emerging industry demonstration cluster, unique biopharmaceutical industry innovation center"Several Measures" to give significant support to innovative research and development enterprisesFor example, in improving the ability of research and development innovation, new support for clinical trials inside and outside China for improved drugs has accumulated 17 million yuan, 3 million yuan in rewards for the first three countries in the country through the consistency evaluation of generic drugs, and 3 million yuan in incentives for enterprises to undertake major special projects and build a national innovation platform, supported by state funding of 1:1For innovative drugs, modified new drugs, generic drugs to obtain a registration certificate and the first time to obtain industrialization, to give 10 million yuan, 5 million yuan, 3 million yuan of heavy prize support, etc;at the same time, "Several Measures" to the biopharmaceutical enterprises' main business sales revenue of 100 million yuan, 500 million yuan, 1 billion yuan to give gradient incentives, a cumulative amount of up to 18 million yuan;"Several Measures" also mentioned, focus on the development of biomedical research clinical, testing, review and approval and market entry, the national provincial and municipal clinical medical research center to give 2 million - 10 million yuan ladder award, to promote the "industrial park, new incubators, industrial funds and industrial alliance" integrated park development modelthe Action Plan, through the comprehensive promotion of eight major projects, focus on the construction of "platform and base", focus on the whole industrial chain innovation, and constantly optimize the ecological environment created by innovation and entrepreneurship, and promote the integration of innovation chain, industrial chain, financial chain, talent chain and supply chainThese eight projects include innovative drug development engineering, medical device innovation engineering, new industry-generating engineering, enterprise multiplier development engineering, platform base upgrading project, clinical research collaborative engineering, investment expansion project, demonstration application Huimin project, in addition, the "14th Five-Year Plan for biomedicine and health industry development" (draft for comments) issued at the 7th Xiamen Biopharmaceutical Innovation Conference shows that in the next "five-year plan", it is proposed to focus on the development of innovative drugs, high-performance medical equipment, high-value functional food, biomanufacturing and biological breeding, emerging marine biology and marine technology, biomedical services, digital health, digital health equipment equipment, health services in these nine directionsXiamen is an early area of China's biopharmaceutical industryAfter many years of sustained high-speed growth, Xiamen's biopharmaceutical industry is developing rapidlyIn 2019, Xiamen's biomedicine and health industry achieved a main revenue of 81 billion yuan, an output value of 66.5 billion yuan, into the first batch of national strategic emerging industrial clusters In addition, Xiamen Biopharmaceutical Port, located in Haitang, after years of relay development, in 2019 in the national biopharmaceutical industrial park comprehensive competitiveness ranking ranked 13th.